

GCG-Oncomine Pan-Cancer Cell-Free (LBx) Assay

Are you having trouble with tissue biopsy or insufficient amount of tissue for further mutation analysis test?


Liquid Biopsy is

An emerging technology developed to overcome the limitations of tissue biopsy and provide more options for patients and physicians battling cancer.

The Science behind Liquid Biopsy

In cancer patients, a fraction of the cfDNA is tumor derived. These tumor derived DNA, called **circulating tumor DNA(ctDNA)**, carry the same genetic mutations present in the primary tumor cells.

With the right sensitivity and specificity, these can be used for diagnosis, treatment decisions and monitoring of cancers.



The Need in the Market

Tissue Biopsy



Invasive



Not always possible depending on tumor location



Not representative of the entire tumor

Liquid Biopsy



Non-Invasive




More Accessible Sample collection



More 'complete' picture of tumor

GCG-Oncomine Pan-Cancer Cell-Free (LBx) Assay

Clinical Indications



- Stage 3-4 Advanced, Metastatic and/or Recurrent solid tumor patients
- When Tissue Biopsy is not an option
- Carcinoma of Unknown Primary (CUP) Patients

- Stage I/II Solid Tumor Patients
- Hematologic Malignance Patients
- Patients Responding to anti-cancer therapy or are at stable state (Stable Disease, SD)

Test Process



Features



Accepted Sample
20 ml Whole Blood
2 x 10ml Streck cfDNA Tubes



Turnaround Time
18 Calendar Days



Analyzed Genes
52 genes Oncomine
Pan-Cancer Cell-free Assay



Oncomine Knowledge Report, with published therapeutic interventions and global clinical trials, will be provided.



Quality accredited Lab by **College of American Pathologists (CAP)** with over 8 years experiences.



Counselling and QnA services offered by the medical doctors.

Oncomine Pan-Cancer Cell-Free Assay

Hospot genes	ALK	BRAF	EGFR	ERBB2(HER2)	IDH1	IDH2	KIT	KRAS	NRAS	PDGFRA
	AKT1	AR	ARAF	CHEK2	CTNNB1	DDR2	ERBB3	ESR1	FGFR1	FGFR2
	FGF3	FGFR4	FLT3	GNA11	GNAQ	GNAS	HRAS	MAP2K1	MAP2K2	MET
	MTOR	NTRK1	NTRK3	PIK3CA	RAF1	RET	ROS1	SF3B1	SMAD4	SMO
Tumor Suppressor Genes	APC	FBXW7	PTEN	TP53						
CNV	EGFR	ERBB2(HER2)	MYC	CCND1	CCND2	CCND3	CDK4	CDK6	FGFR1	FGFR2
	FGFR3	MET								
RNA Fusion	ALK	BRAF	ERG	ETV1	FGFR1	FGFR2	FGFR3	MET	NTRK1	NTRK3
	RET	ROS1								

Oncomine Pan-Cancer LBx-TS[EN]-v1.1-EX-09D-20.09.18

Performance Specifications

	Reporting Threshold	Analytical Sensitivity		Analytical Specificity	
SNVs	0.1*-0.5% (2-3 molecules)	LOD	<1%	92.1-96.9%	99.9%
			≥1%	100%	
Indel	0.1*-0.5% (2-3 molecules)	LOD	<1%	92.1-96.9%	99.9%
			≥1%	100%	
Fusions	1.0 % (2 molecules)	100%		100%	
CNVs	2.3 - 4.0 copies (gain)	100%		100%	
	1.0 copies (loss)				

* Based on cfDNA input of 20ng

Why GC Genome is the "BEST" Choice for liquid biopsy

Best in Class

Precision Oncology Dx service with an affordable price

Equipped

with cutting edge NGS platform

Supportive

Q&A and Follow up Services from internal Medical Doctors

Trustworthy

laboratory with CAP accreditation and experienced technicians

About GC Genome

Clinical genomic diagnostics company with state-of the art CAP accredited laboratory and broad customer base of over 300 entities ranging from major university hospitals to private clinics. Pioneering genomics based diagnostics and analytics platform with proprietary technology for analysis of human genomic data for identification and prediction of major disease areas.